CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Insuficiencia cardiaca

Biblioteca de referencias del ESPACIO de insuficiencia cardiaca

Detalles
G
ESPACIO de insuficiencia cardiaca › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los ensayos, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

Descargar en RIS (209 referencias)

Artículos y guías en PubMed (162)

  1. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66. doi:10.1016/S0140-6736(11)60101-3 · PMID 21315441G2
  2. Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD, et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail. 2024;26(1):18-33. doi:10.1002/ejhf.3106 · PMID 38131233C7
  3. Anguita Gámez M, Esteban Fernández A, García Márquez M, Del Prado N, Elola Somoza FJ, Anguita Sánchez M. Age and stabilization of admissions for heart failure in Spain (2006-2019). The beginning of the end of the "epidemic"? Rev Esp Cardiol (Engl Ed). 2023;76(4):272-274. doi:10.1016/j.rec.2022.08.009 · PMID 36228960H2G3
  4. Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, Jiménez Navarro M, Alonso-Pulpón L, Muñiz García J, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol. 2008;61(10):1041-9. doi:10.1016/s1885-5857(09)60007-4 · PMID 18817680G3
  5. Anguita Sánchez M, Bonilla Palomas JL, García Márquez M, Bernal Sobrino JL, Fernández Pérez C, Elola Somoza FJ. Temporal trends in hospitalizations and in-hospital mortality in heart failure in Spain 2003-2015: differences between autonomous communities. Rev Esp Cardiol (Engl Ed). 2020;73(12):1075-1077. doi:10.1016/j.rec.2020.05.040 · PMID 32800487G3
  6. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. doi:10.1056/NEJMoa0908355 · PMID 19920054I1G2
  7. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 · PMID 34449189I1G2
  8. Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M, et al. Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA. 2025;333(22):1965-1976. doi:10.1001/jama.2025.3833 · PMID 40159390I1
  9. Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. 2025;31(8):2640-2646. doi:10.1038/s41591-025-03671-1 · PMID 40159279I1
  10. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928 · PMID 32222134I1G2C4C6
  11. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845 · PMID 33264825I1G2
  12. Baptista R, Rodrigues AM, Bernardo F, Mendes LL, Franco F, Pimenta J, et al. Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. Eur Heart J. 2026;47(34):4806-4822. doi:10.1093/eurheartj/ehag030 · PMID 41641552H2G3
  13. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. doi:10.1056/NEJMoa043399 · PMID 15659722G2
  14. Bavendiek U, Großhennig A, Schwab J, Berliner D, Rieth A, Maier LS, et al. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2025;393(12):1155-1165. doi:10.1056/NEJMoa2415471 · PMID 40879434I1G2
  15. Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation. 2025;152(20):1411-1422. doi:10.1161/CIRCULATIONAHA.125.076575 · PMID 40884036I1G5
  16. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183 · PMID 33200892G2
  17. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-50. doi:10.1056/NEJMoa032423 · PMID 15152059G2
  18. Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362-4373. doi:10.1093/eurheartj/ehac401 · PMID 35900838C7
  19. Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025;406(10510):1341-1350. doi:10.1016/S0140-6736(25)01665-4 · PMID 40897189I1G2
  20. Cequier Á, Bueno H, Macaya C, Bertomeu V, González-Juanatey JR, Íñiguez A, et al. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020. Rev Esp Cardiol (Engl Ed). 2023;76(7):519-530. doi:10.1016/j.rec.2022.09.017 · PMID 36493955H2G3C7
  21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49. doi:10.1056/NEJMoa050496 · PMID 15753115G2
  22. Cobo Marcos M, Trullàs JC, Perez-Silvestre J, Miró Ò, Quiroga B, Mirabet S, et al. Urinary sodium to guide diuretic therapy in acute heart failure: results of a national survey. ESC Heart Fail. 2026;13(1). doi:10.1093/eschf/xvag006 · PMID 41711714G3
  23. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Böhm M, Coats AJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009;11(9):872-80. doi:10.1093/eurjhf/hfp104 · PMID 19648605C4C6
  24. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-52. doi:10.1056/NEJM198606123142404 · PMID 3520315I1G2
  25. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-10. doi:10.1056/NEJM199108013250502 · PMID 2057035I1G2
  26. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. doi:10.1056/NEJMoa010713 · PMID 11759645I1G2
  27. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301 · PMID 2883575I1G2
  28. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613-25. doi:10.1002/ejhf.566 · PMID 27324686G3
  29. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169 · PMID 30312372C7
  30. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90. doi:10.1016/s0140-6736(00)04560-8 · PMID 11356434I1G2
  31. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C7
  32. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022;80(2):95-108. doi:10.1016/j.jacc.2022.04.048 · PMID 35798455I1
  33. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-33. doi:10.1056/NEJM199702203360801 · PMID 9036306I1G2
  34. Docherty KF, Lam CSP, Rakisheva A, Coats AJS, Greenhalgh T, Metra M, et al. Heart failure diagnosis in the general community - Who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2023;25(8):1185-1198. doi:10.1002/ejhf.2946 · PMID 37368511C7
  35. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. PMID 10376614I1G2C4
  36. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821-8. PMID 8104270I1
  37. Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. doi:10.1161/CIRCHEARTFAILURE.120.008193 · PMID 34923848I1
  38. Elmegaard M, Køber L, Ersbøll MK, Lange T, Tuxen CD, Mouridsen MR, et al. A Randomized Clinical Implementation Trial Testing a Digital Strategy to Increase SGLT2 Inhibitor Initiation in Heart Failure. JACC Heart Fail. 2026;14(10):103176. doi:10.1016/j.jchf.2026.103176 · PMID 42274438G3
  39. Escobar C, Varela L, Palacios B, Capel M, Sicras A, Sicras A, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964. doi:10.1186/s12913-020-05828-9 · PMID 33081776H2
  40. Ezekowitz JA, Colin-Ramirez E, Ross H, Escobedo J, Macdonald P, Troughton R, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5 · PMID 35381194C7
  41. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002;82(2):149-58. doi:10.1016/s0167-5273(01)00600-3 · PMID 11853901I1
  42. Farré N, Vela E, Clèries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. PLoS One. 2017;12(2):e0172745. doi:10.1371/journal.pone.0172745 · PMID 28235067H2
  43. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419 · PMID 21366472I1G2C7
  44. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017;318(8):713-720. doi:10.1001/jama.2017.10565 · PMID 28829876G2
  45. Fernández-Cisnal A, Mollar A, Miñana G, de la Espriella R, Santas E, Lorenzo M, et al. The Expanding Role of Carbohydrate Antigen 125 in Heart Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review. Card Fail Rev. 2026;12:e31. doi:10.15420/cfr.2025.40 · PMID 42865763C7
  46. Ferreira JP, Packer M, Sattar N, Butler J, Pocock SJ, Anker SD, et al. Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme. Eur J Heart Fail. 2024;26(4):788-802. doi:10.1002/ejhf.3166 · PMID 38439582C7
  47. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. doi:10.1093/eurheartj/ehi115 · PMID 15642700I1G2C4C6
  48. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33-44. doi:10.1056/NEJMoa2409134 · PMID 39213194I1
  49. Furuland H, Larsson AO, Uhde M, Parv K, Almstedt M, Cars T, et al. Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database). J Intern Med. 2026;300(2):179-192. doi:10.1111/joim.70087 · PMID 41884993G3
  50. G-CHF Investigators, Joseph P, Roy A, Lonn E, Störk S, Floras J, et al. Global Variations in Heart Failure Etiology, Management, and Outcomes. JAMA. 2023;329(19):1650-1661. doi:10.1001/jama.2023.5942 · PMID 37191704G3
  51. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332-43. doi:10.1001/jama.297.12.1332 · PMID 17384438I1
  52. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132-142. doi:10.1056/NEJMoa2305434 · PMID 38197816I1
  53. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6. doi:10.1016/S0140-6736(03)14284-5 · PMID 13678870I1G2
  54. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-366. doi:10.1016/j.jacc.2018.04.070 · PMID 30025570G3
  55. Greene SJ, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, et al. Median Survival Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction Prescribed Quadruple Medical Therapy. Eur J Heart Fail. 2026;pii: xuag172. doi: 10.1093/ejhf/xuag172. doi:10.1093/ejhf/xuag172 · PMID 42153425G3
  56. Gómez-Batiste X, Martínez-Muñoz M, Blay C, Amblàs J, Vila L, Costa X, et al. Identifying patients with chronic conditions in need of palliative care in the general population: development of the NECPAL tool and preliminary prevalence rates in Catalonia. BMJ Support Palliat Care. 2013;3(3):300-8. doi:10.1136/bmjspcare-2012-000211 · PMID 24644748C7
  57. Hacil A, Antakly-Hanon Y, Lacour A, David JP, Khalifa T, Piccoli M, et al. Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2025;13(12):102428. doi:10.1016/j.jchf.2025.02.011 · PMID 40272336G3
  58. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61-73. doi:10.1016/S0140-6736(18)32484-X · PMID 30429050C4C6C7
  59. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C4C6
  60. Hausleiter J, Stocker TJ, Geisler T, Lurz P, Rottbauer W, Lubos E, et al. Tricuspid-Valve Intervention in Heart Failure. N Engl J Med. 2026;395(14):1363-1373. doi:10.1056/NEJMoa2606934 · PMID 42670975G2
  61. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816 · PMID 32970396G2C4C6
  62. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 · PMID 35363499G1
  63. Herrmann JJ, Brunner-La Rocca HP, Baltussen LEHJM, Beckers-Wesche F, Bekkers SCAM, Bellersen L, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med. 2025;31(6):2062-2068. doi:10.1038/s41591-025-03628-4 · PMID 40159556C7
  64. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-2679. doi:10.1093/eurheartj/ehx355 · PMID 28934837C7
  65. Inciardi RM, Volterrani M, Savarese G, Vaduganathan M, Oriecuia C, Lombardi CM, et al. Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry. Eur J Heart Fail. 2025;27(12):2691-2704. doi:10.1002/ejhf.70074 · PMID 41408894G3
  66. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. doi:10.1056/EVIDoa2300286 · PMID 38320489I1G5
  67. Januzzi JL Jr, Rosenmeier JB, Ely Pizzato P, Quintana-Hayashi MP, Chan LM, Johannesson P, et al. Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial. Circulation. 2026;doi: 10.1161/CIRCULATIONAHA.126.082763. doi:10.1161/CIRCULATIONAHA.126.082763 · PMID 42668430G2
  68. Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Chatur S, Claggett BL, et al. Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases: A Randomized Clinical Trial. JAMA. 2024;332(22):1900-1911. doi:10.1001/jama.2024.21060 · PMID 39392741G2
  69. Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Loiacono MM, Harris RC, et al. High-Dose Versus Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. Circulation. 2026;153(11):798-806. doi:10.1161/CIRCULATIONAHA.125.077801 · PMID 41212981G2
  70. Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Loiacono MM, Harris RC, et al. High-dose vs. standard-dose influenza vaccine in heart failure: the FLUNITY-HD trial. Eur Heart J. 2026;pii: ehag709. doi: 10.1093/eurheartj/ehag709. doi:10.1093/eurheartj/ehag709 · PMID 42667303G2
  71. Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Chatur S, Claggett BL, et al. Electronic Nudges to Increase Influenza Vaccination Uptake in Young and Middle-Aged Patients with Heart Failure: A Prespecified Analysis of the NUDGE-FLU-CHRONIC Trial. Circ Heart Fail. 2026;doi: 10.1161/CIRCHEARTFAILURE.126.014891. doi:10.1161/CIRCHEARTFAILURE.126.014891 · PMID 42667600G2
  72. Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025;151(9):601-611. doi:10.1161/CIRCULATIONAHA.124.072771 · PMID 39556242I1
  73. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199-2209. doi:10.1016/S0140-6736(22)02083-9 · PMID 36347265I1G2C7
  74. Kirk B, Cawthon PM, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, et al. The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. 2024;53(3). doi:10.1093/ageing/afae052 · PMID 38520141C7
  75. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392(10152):1047-1057. doi:10.1016/S0140-6736(18)31880-4 · PMID 30153985G2
  76. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319-31. doi:10.1001/jama.297.12.1319 · PMID 17384437I1
  77. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840-8. doi:10.1016/S0140-6736(09)61913-9 · PMID 19922995I1G2
  78. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 · PMID 37622681G2
  79. Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, et al. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. J Am Coll Cardiol. 2025;85(10):971-984. doi:10.1016/j.jacc.2024.11.014 · PMID 39566872C7
  80. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi:10.1056/NEJMoa1608029 · PMID 27571011G2
  81. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;pii: ehag100. doi: 10.1093/eurheartj/ehag100. doi:10.1093/eurheartj/ehag100 · PMID 42661420G1
  82. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398(10304):991-1001. doi:10.1016/S0140-6736(21)01754-2 · PMID 34461042G2
  83. Llorens P, Javaloyes P, Martín-Sánchez FJ, Jacob J, Herrero-Puente P, Gil V, et al. Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure. Clin Res Cardiol. 2018;107(10):897-913. doi:10.1007/s00392-018-1261-z · PMID 29728831G3
  84. Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013;15(4):465-76. doi:10.1093/eurjhf/hfs189 · PMID 23186936G3
  85. Lund LH, Maggioni AP, Crespo-Leiro MG, Laroche C, Gotsman I, Pojskic B, et al. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. Eur Heart J. 2026;47(19):2326-2341. doi:10.1093/eurheartj/ehaf1074 · PMID 41736503G3
  86. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. doi:10.1056/NEJMoa1707855 · PMID 29385358C7
  87. Martínez Santos P, Bover Freire R, Esteban Fernández A, Bernal Sobrino JL, Fernández Pérez C, Elola Somoza FJ, et al. In-hospital Mortality and Readmissions for Heart Failure in Spain. A Study of Index Episodes and 30-Day and 1-year Cardiac Readmissions. Rev Esp Cardiol (Engl Ed). 2019;72(12):998-1004. doi:10.1016/j.rec.2019.02.004 · PMID 30930253G3
  88. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. doi:10.1056/NEJMoa0805450 · PMID 19001508G2
  89. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689 · PMID 30145929I1
  90. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-71. doi:10.1016/S0140-6736(03)14283-3 · PMID 13678869I1G2
  91. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077 · PMID 25176015I1G2
  92. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303 · PMID 31535829I1G2
  93. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-1952. doi:10.1016/S0140-6736(22)02076-1 · PMID 36356631G2C6C7
  94. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019;380(17):1618-1627. doi:10.1056/NEJMoa1900486 · PMID 30883052G2
  95. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924 · PMID 36648467I1G2
  96. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023;389(11):975-986. doi:10.1056/NEJMoa2304968 · PMID 37632463I1G2C7
  97. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. doi:10.1016/j.jacc.2023.04.019 · PMID 37212758I1
  98. Molina A, Vicente M, Gasol M, Carbonell P, López P, Pontes C. A Drug Utilization Study of Sacubitril/Valsartan in Catalonia. Rev Esp Cardiol (Engl Ed). 2019;72(7):593-595. doi:10.1016/j.rec.2018.08.004 · PMID 30172655C2
  99. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. doi:10.1056/NEJMoa013474 · PMID 11907286G2
  100. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38. doi:10.1056/NEJMoa0906431 · PMID 19723701G2
  101. Mulder BA, van Veldhuisen DJ, Crijns HJ, Böhm M, Cohen-Solal A, Babalis D, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14(10):1171-8. doi:10.1093/eurjhf/hfs100 · PMID 22764183C4C6
  102. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094 · PMID 36027559I1G2C7
  103. Nielsen JC, Svendsen JH, Johansen JB, Larsen JM, Larroudé CE, Poulsen SH, et al. Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark. Lancet. 2026;408(10561):1175-1185. doi:10.1016/S0140-6736(26)01597-7 · PMID 42673980G2
  104. Núñez J, Llàcer P, Bertomeu-González V, Bosch MJ, Merlos P, García-Blas S, et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study. JACC Heart Fail. 2016;4(11):833-843. doi:10.1016/j.jchf.2016.06.007 · PMID 27522630C7
  105. Núñez J, Llàcer P, García-Blas S, Bonanad C, Ventura S, Núñez JM, et al. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. Am J Med. 2020;133(3):370-380.e4. doi:10.1016/j.amjmed.2019.07.041 · PMID 31422111C7
  106. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018;379(24):2297-2306. doi:10.1056/NEJMoa1805374 · PMID 30145927G2
  107. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X · PMID 32871100I1
  108. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-55. doi:10.1056/NEJM199605233342101 · PMID 8614419I1G2
  109. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. doi:10.1056/NEJM200105313442201 · PMID 11386263I1G2C4C6
  110. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 · PMID 32865377I1G2
  111. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 · PMID 39555826G2
  112. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. doi:10.1056/NEJMoa032292 · PMID 14610160I1
  113. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021;385(20):1845-1855. doi:10.1056/NEJMoa2104508 · PMID 34758252I1G2
  114. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. doi:10.1056/NEJM199909023411001 · PMID 10471456I1G2
  115. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-7. doi:10.1016/s0140-6736(00)02213-3 · PMID 10821361I1
  116. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. doi:10.1056/NEJMoa030207 · PMID 12668699I1G2
  117. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731 · PMID 24716680I1G2
  118. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956 · PMID 34449181I1G2
  119. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371(9627):1839-47. doi:10.1016/S0140-6736(08)60601-7 · PMID 18479744C4C6
  120. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-68. doi:10.1093/eurheartj/ehu385 · PMID 25176939I1G2
  121. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-1904. doi:10.1016/S0140-6736(20)32339-4 · PMID 33197395I1G2C4C6C7
  122. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7 · PMID 12853193I1G2
  123. Pérez-Rivera JÁ, Bonilla-Palomas JL, Diez-Villanueva P, Jiménez-Méndez C, Solla-Suárez P, López-Azor JC, et al. Nutritional intervention in older outpatients with chronic heart failure and malnutrition or at risk of malnutrition: the BOCADOS-IC randomized trial. Rev Esp Cardiol (Engl Ed). 2026;pii: S1885-5857(26)00158-1. doi: 10.1016/j.rec.2026.07.001. doi:10.1016/j.rec.2026.07.001 · PMID 42476223C7
  124. Rasoul D, Zhang J, Farnell E, Tsangarides AA, Chong SC, Fernando R, et al. Continuous infusion versus bolus injection of loop diuretics for acute heart failure. Cochrane Database Syst Rev. 2024;5(5):CD014811. doi:10.1002/14651858.CD014811.pub2 · PMID 38775253I1
  125. Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016;68(5):473-482. doi:10.1016/j.jacc.2016.05.043 · PMID 27470455C7
  126. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95. doi:10.1503/cmaj.050051 · PMID 16129869C7
  127. Rodríguez-Padial L, Bertomeu V, Elola FJ, Anguita M, Fernández Lozano I, Silva L, et al. Quality Improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry. J Am Coll Cardiol. 2016;68(10):1140-2. doi:10.1016/j.jacc.2016.07.723 · PMID 27585513G3
  128. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43. doi:10.1056/NEJMoa012175 · PMID 11794191G2
  129. Salguero-Bodes R, Arribas-Ynsaurriaga F. Ten years of the RECALCAR registry: reflections on cardiovascular care in Spain. Rev Esp Cardiol (Engl Ed). 2023;76(7):500-502. doi:10.1016/j.rec.2023.01.015 · PMID 37019206G3
  130. Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Ups J Med Sci. 2019;124(1):65-69. doi:10.1080/03009734.2018.1490831 · PMID 30092697G3
  131. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-112. doi:10.1056/NEJMoa065181 · PMID 17105757I1
  132. Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, et al. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023;389(15):1380-1389. doi:10.1056/NEJMoa2306037 · PMID 37634135C7
  133. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655 · PMID 31475794I1G2
  134. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 · PMID 36027570I1G2
  135. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 · PMID 39225278I1G2C4C6
  136. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501 · PMID 2057034I1G2
  137. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685-91. doi:10.1056/NEJM199209033271003 · PMID 1463530I1G2
  138. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1833-1842. doi:10.1056/NEJMoa2300525 · PMID 36876753G2
  139. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-2318. doi:10.1056/NEJMoa1806640 · PMID 30280640G2
  140. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. doi:10.1016/S0140-6736(10)61198-1 · PMID 20801500I1G2
  141. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95. doi:10.1056/NEJMoa1009540 · PMID 21073365G2
  142. Tavazzi L, Senni M, Metra M, Gorini M, Cacciatore G, Chinaglia A, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6(3):473-81. doi:10.1161/CIRCHEARTFAILURE.112.000161 · PMID 23476054G3
  143. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-57. doi:10.1056/NEJMoa042934 · PMID 15533851I1G2
  144. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. PMID 10023943I1G2C4
  145. Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014;2(1):24-31. doi:10.1016/j.jchf.2013.07.009 · PMID 24622115C7
  146. Trullàs JC, Pérez-Calvo JI, Conde-Martel A, Llàcer Iborra P, Suárez Pedreira I, Ormaechea G, et al. Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry. Med Clin (Barc). 2021;157(1):1-9. doi:10.1016/j.medcli.2020.05.059 · PMID 32829921G3
  147. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44(5):411-421. doi:10.1093/eurheartj/ehac689 · PMID 36423214I1G2C7
  148. Trullàs JC, Moreno-García MC, Mittelbrunn-Alquézar V, Conde-Martel A, Soler-Rangel L, Montero-Pérez-Barquero M, et al. The RICA-2 registry: design and baseline characteristics of the first 1,000 patients. Rev Clin Esp (Barc). 2024;224(8):522-533. doi:10.1016/j.rceng.2024.07.008 · PMID 39053884G3
  149. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-128. doi:10.1016/S0140-6736(20)30748-0 · PMID 32446323C7
  150. van der Meer P, van Essen BJ, Viljoen C, Böhm M, Jackson A, Hilfiker-Kleiner D, et al. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. Eur Heart J. 2025;46(11):1017-1027. doi:10.1093/eurheartj/ehae559 · PMID 39221911C7
  151. van Veldhuisen DJ, Rienstra M, Mosterd A, Alings M, Voors AA, Damman K, et al. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial. Nat Med. 2026;32(7):2647-2653. doi:10.1038/s41591-026-04406-6 · PMID 42108270I1
  152. Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med. 2022;28(12):2504-2511. doi:10.1038/s41591-022-02102-9 · PMID 36522606C4C6
  153. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851 · PMID 30415601G2C4C6
  154. Vincentelli A, Martin AC, Guihaire J, Bouchot O, Lebreton G, Pozzi M, et al. Auto-regulated bioprosthetic total artificial heart as bridge to transplantation: the EFICAS study. Eur Heart J. 2026;pii: ehag704. doi: 10.1093/eurheartj/ehag704. doi:10.1093/eurheartj/ehag704 · PMID 42670784G2
  155. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1 · PMID 35228754I1G2C4C6
  156. Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, et al. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). Eur Heart J. 2026;47(32):4357-4374. doi:10.1093/eurheartj/ehag500 · PMID 42366993C7
  157. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-35. doi:10.1161/CIRCULATIONAHA.105.582320 · PMID 16143696I1
  158. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389 · PMID 30415602G2
  159. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. doi:10.1016/S0140-6736(03)14285-7 · PMID 13678871I1G2
  160. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492 · PMID 21073363I1G2C7
  161. Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025;406(10510):1351-1362. doi:10.1016/S0140-6736(25)01682-4 · PMID 40897188I1
  162. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720 · PMID 26378978I1G2

Otros documentos con DOI (1)

  1. Anguita Sánchez M, Bonilla Palomas JL, García Márquez M, Bernal Sobrino JL, Fernández Pérez C, Elola Somoza FJ. Tendencias temporales en ingresos y mortalidad hospitalaria por insuficiencia cardiaca en España, 2003-2015: diferencias por comunidades autónomas. Revista Española de Cardiología. 2020;73(12):1075-1077. doi:10.1016/j.recesp.2020.05.025G3

Fichas técnicas (CIMA, AEMPS) (39)

  1. Ficha técnica de carboximaltosa férrica. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 69771I1C5C1C4I2C6C7
  2. Ficha técnica de dapagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 112795007I1G5C5C1C4I2C6
  3. Ficha técnica de empagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 114930014I1C5C1C4I2C6
  4. Ficha técnica de eplerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 66356I1C5C1C4I2C6C7
  5. Ficha técnica de espironolactona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 39059I1C5C1C4I2C6C7
  6. Ficha técnica de finerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1211616007I1C5C1C4I2C6C7
  7. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 05316010I1C5C1C4I2C6
  8. Ficha técnica de registro 09539001. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 09539001I1
  9. Ficha técnica de registro 1110717003. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1110717003I1C5
  10. Ficha técnica de registro 1171173002. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1171173002C7
  11. Ficha técnica de registro 1171179001. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1171179001C7
  12. Ficha técnica de registro 1221681001. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1221681001I1C5
  13. Ficha técnica de registro 1231716006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1231716006I1
  14. Ficha técnica de registro 1241906001. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1241906001I1C5
  15. Ficha técnica de registro 23850. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 23850C7
  16. Ficha técnica de registro 24408. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 24408I1
  17. Ficha técnica de registro 34566. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 34566I1C7
  18. Ficha técnica de registro 39968. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 39968I1C5C7
  19. Ficha técnica de registro 39969. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 39969I1
  20. Ficha técnica de registro 54503. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 54503I1C4C6
  21. Ficha técnica de registro 54575. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 54575C7
  22. Ficha técnica de registro 54633. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 54633C7
  23. Ficha técnica de registro 57127. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 57127C7
  24. Ficha técnica de registro 59564. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 59564I1C5
  25. Ficha técnica de registro 60450. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 60450I1C5
  26. Ficha técnica de registro 61894. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 61894I1C5
  27. Ficha técnica de registro 63355. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 63355I1C5
  28. Ficha técnica de registro 64154. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 64154C7
  29. Ficha técnica de registro 64971. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 64971I1C5
  30. Ficha técnica de registro 68327. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 68327I1C5C4I2C6
  31. Ficha técnica de registro 70323. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 70323I1C5
  32. Ficha técnica de registro 70741. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 70741I1C5C4I2C6
  33. Ficha técnica de registro 73926. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 73926I1C5C4I2C6
  34. Ficha técnica de registro 81030. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 81030I1C4I2C6
  35. Ficha técnica de registro 85914. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 85914C7
  36. Ficha técnica de registro 89669. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 89669C7
  37. Ficha técnica de registro 90834. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 90834I1
  38. Ficha técnica de sacubitrilo/valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1151058003I1C5C1C4I2C6
  39. Ficha técnica de vericiguat. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 08/10/2026. CIMA, registro 1211561023I1C1C4I2C6

Ensayos en marcha (ClinicalTrials.gov) (7)

  1. APPLE TREE. Empagliflozina frente a dapagliflozina, aleatorizado por centros dentro de la historia clínica electrónica, en diabetes, enfermedad renal crónica e insuficiencia cardiaca. ClinicalTrials.gov, NCT06642272; 17.200 pacientes · fase IV · resultados primarios previstos: diciembre de 2028 · promotor: Herlev and Gentofte Hospital (Dinamarca). Consultado el 08/10/2026. NCT06642272I1G5
  2. BalanceD-HF. Balcinrenona/dapagliflozina frente a dapagliflozina sola en insuficiencia cardiaca con función renal reducida y un episodio reciente: muerte cardiovascular y eventos de insuficiencia cardiaca. ClinicalTrials.gov, NCT06307652; 3.850 pacientes · fase III · resultados primarios previstos: abril de 2027 · promotor: AstraZeneca. Consultado el 08/10/2026. NCT06307652I1G5
  3. CRACOVIA-HF. Sacubitrilo/valsartán frente a ramipril sobre la función y el remodelado del ventrículo izquierdo en insuficiencia cardiaca isquémica con FEVI ligeramente reducida. ClinicalTrials.gov, NCT05508035; 488 pacientes · fase III · resultados primarios previstos: agosto de 2028 · promotor: John Paul II Hospital (Cracovia). Consultado el 08/10/2026. NCT05508035I1
  4. DAPA-ICU. Dapagliflozina frente a placebo para la protección cardiorrenal tras el alta de cuidados intensivos. ClinicalTrials.gov, NCT07025629; 600 pacientes · fase III · resultados primarios previstos: enero de 2029 · promotor: Assistance Publique - Hôpitaux de Paris. Consultado el 08/10/2026. NCT07025629I1G5
  5. MAINSTREAM. Sacubitrilo/valsartán frente a placebo en la prevención primaria de la cardiotoxicidad del tratamiento del cáncer de mama. ClinicalTrials.gov, NCT05465031; 600 pacientes · fase IV · resultados primarios previstos: diciembre de 2027 · promotor: Silesian Centre for Heart Diseases. Consultado el 08/10/2026. NCT05465031I1
  6. Prevent-HF. Baxdrostat con dapagliflozina frente a dapagliflozina sola para prevenir la insuficiencia cardiaca en diabetes tipo 2 con enfermedad cardiovascular e hipertensión. ClinicalTrials.gov, NCT06677060; 11.300 pacientes · fase III · resultados primarios previstos: diciembre de 2029 · promotor: AstraZeneca. Consultado el 08/10/2026. NCT06677060I1G5
  7. SAVA-TTR. Sacubitrilo/valsartán en amiloidosis cardiaca por transtiretina con FEVI ≤40%: cambio de la función sistólica. ClinicalTrials.gov, NCT06712030; 114 pacientes · fase III, aún sin reclutar · resultados primarios previstos: abril de 2027 · promotor: Hospital Universitario Puerta de Hierro. Consultado el 08/10/2026. NCT06712030I1
La lista se genera sola a partir de lo que citan los módulos (PubMed por PMID, DOI resuelto en PubMed o en CrossRef, CIMA y ClinicalTrials.gov) y se rehace al regenerar el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.